Vertex to Present New Data on Exagamglogene Autotemcel (exa-

- New data including longer duration follow-up from SCD and TDT pivotal trials accepted for oral presentation –


- Five additional abstracts accepted for poster presentation -

...

Related Keywords

Boston , Massachusetts , United States , Australia , London , City Of , United Kingdom , America , American , Exagamglogene Autotemcel , Instagram , Vertex Pharmaceuticals Incorporated Nasdaq , Facebook , Youtube , European Hematology Association Congress , Improvements In Health , Companies To Work , Occlusive Crisis On Health , American Society Of Hematology , Linkedin , Exchange Commission , Vertex Pharmaceuticals Incorporated , Annual Meeting , Severe Sickle Cell , Health Related Quality , Life After Exagamglogene Autotemcel , Transfusion Dependent Beta , Patients With Severe Sickle Cell , Status Among Patients , Cohort Study , Recent Vaso Occlusive Crisis , Sickle Cell , Sickle Cell Disease Prevalence , Model Using , Foreign Born State Specific Population , New England Journal , North America , Top Employers , Private Securities Litigation Reform Act , While Vertex , Markets ,